Asset medical lifecycle plan
The challenge
US and EU regulatory agencies provided the client with new guidance on generating supportive evidence for the proposed launch indication and future indications for a breakthrough vaccine. The client team wished to understand the potential impact of this information on the lifecycle and to develop an updated indication strategy.
Our solution
We identified key criteria for populations of interest and the relevant decision-making criteria to aid prioritization. We also assessed potential indications, including their evidence and regulatory needs, and facilitated a team workshop to align on prioritization of data generation initiatives and indications.
The results
Ultimately, we leveraged guidance received from regulatory authorities and input from the cross-functional team to develop an indication expansion strategy for long-term success.
Jump to a slide with the slide dots.
CNS indication/ Endpoint prioritization
A biopharma client with an early clinical stage compound, showing efficacy across multiple neuropsychiatric conditions, wished to prioritize...
Read moreMedical Affairs omnichannel platform
A large biopharma client objective aimed to optimize its omnichannel (OC) approach for HCP and patient Medical Education...
Read moreRare respiratory claims data analysis
A top biopharma client wanted to understand diagnosis and treatment patterns for a rare respiratory disease only recently associated as a sequela....
Read more